Printer Friendly

Hepatitis C recurrence after liver transplant generally mild, study finds.

Among patients who have undergone liver transplantation due to hepatitis C virus (HCV) complications, posttransplant recurrence of infection is generally mild, asymptomatic, and not clinically significant, according to a report by Austrian surgeons.

At Digestive Disease Week 2003, held in Orlando, FL in May, Lukas Hinterhuber, MD described 118 patients who underwent liver transplantation for HCV between 1986 and 2003 at the University of Innsbruck. Of these, 84 patients were male, 34 were female, mean patient age was 56 years, and mean donor age was 35 years.

Posttransplant HCV recurrence tended to be mild portal, lobular, or mixed. Cholestatic hepatitis developed in 12 patients, 9 of whom died. The incidence of cirrhosis with HCV recurrence was very low-approximately 5%.

"Except for the cholestatic type, HCV recurrence did not adversely influence patient or graft survival," reported Hinterhuber. Survival rates ranged from 83% at 1year to 59% at 10 years.

Meeting attendee Charles Kuckel, MD, commented that his experience at the University of Medicine and Dentistry of New Jersey in Newark has been much different. "We've had a lot of problems with post-liver transplant HCV recurrence," he said, theorizing that this might be due to the genotype of the virus and/or the older age of the donors (over 37 years).

Kuckel also pointed to the higher percentage of living donors used by the Austrian team-around 25% to 30%. "We use cadaveric donors almost exclusively. That makes a very big difference. You don't know the history [of the donor]. With a living donor, you can test for everything."
COPYRIGHT 2003 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Sep 15, 2003
Previous Article:Genetically speaking, humans closer to rats than to cats.
Next Article:Everolimus superior to azathioprine for cardiac allograft vasculopathy.

Related Articles
Do liver stem cells come from bone marrow?
Liver transplants succeed in many hepatitis C patients.
Current challenges in hepatitis C.
Clinical perspective: battling hepatitis C in our HIV-infected patients.
Kidney, liver transplant study for people with HIV.
Nabi Biopharmaceuticals granted Fast Track Designation by FDA for Civacir to prevent HCV re-infection in liver transplant patients.
Nabi gets positive opinion from FDA panel for injectable hepatitis B drug use after liver transplant.
Study Identifies Factors to Predict Survival After Liver Transplant.
Advanced age doesn't appear to impact risk of death after liver transplant.
Decreasing Need for Liver Transplants for Hepatitis B Patients.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters